Screener
MoonLake Immunotherapeutics MLTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of short-term marketable debt securities | (59,068) | (88,548) |
| Proceeds from maturities of short-term marketable debt securities | 59,166 | 144,829 |
| Purchase of property and equipment | — | (35) |
| Net cash flow provided by investing activities | 98 | 56,246 |
| Cash flow from financing activities | ||
| Proceeds from long-term debt, net of issuance costs | 24,467 | 73,022 |
| Issuance of Class A Ordinary Shares, net of transaction costs | 6,007 | — |
| Proceeds from options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan | 170 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's investing cash flow?
- MoonLake Immunotherapeutics (MLTX) reported investing cash flow of $98K in Q1 2026.
- How has MoonLake Immunotherapeutics's investing cash flow changed year-over-year?
- MoonLake Immunotherapeutics's investing cash flow decreased by 99.8% year-over-year, from $56.25M to $98K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about MoonLake Immunotherapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude